1-(4-methoxy-benzoyl)-2,3-dihydro-1H-quinolin-4-one | 679809-48-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 1-(4-methoxy-benzoyl)-2,3-dihydro-1H-quinolin-4-one
• 英文别名: 2,3-Dihydro-1-(4-methoxybenzoyl)-4(1H)-quinolinone；1-(4-methoxybenzoyl)-2,3-dihydroquinolin-4-one
• CAS: 679809-48-4
• 化学式: C₁₇H₁₅NO₃
• 分子量: 281.311
• InChiKey: JSNSFHVVQRZRPT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  21
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  46.6
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1-(4-methoxy-benzoyl)-2,3-dihydro-1H-quinolin-4-one 、 碘甲烷 在 lithium hexamethyldisilazane 作用下， 以 四氢呋喃 为溶剂， 生成
  参考文献：
  名称：

  Tetrahydro-4-quinolinamines identified as novel P2Y1 receptor antagonists

  摘要：

  High-throughput screening of the GSK compound collection against the P2Y1 receptor identified a novel series of tetrahydro-4-quinolinamine antagonists. Optimal substitution around the piperidine group was pivotal for ensuring activity. An exemplar analog from this series was shown to inhibit platelet aggregation. (C) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2008.09.102
• 作为产物：
  描述：

  2,3-二氢-1H-喹啉-4-酮 、 对甲氧基苯甲酰氯 在 N-甲基吗啉 作用下， 以 二氯甲烷 为溶剂， 生成 1-(4-methoxy-benzoyl)-2,3-dihydro-1H-quinolin-4-one
  参考文献：
  名称：

  Tetrahydro-4-quinolinamines identified as novel P2Y1 receptor antagonists

  摘要：

  High-throughput screening of the GSK compound collection against the P2Y1 receptor identified a novel series of tetrahydro-4-quinolinamine antagonists. Optimal substitution around the piperidine group was pivotal for ensuring activity. An exemplar analog from this series was shown to inhibit platelet aggregation. (C) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2008.09.102

文献信息

• [EN] PGD2 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES<br/>[FR] ANTAGONISTES DE RECEPTEUR DE LA PROSTAGLANDINE D2 POUR LE TRAITEMENT DE MALADIES INFLAMMATOIRES
  申请人：MILLENNIUM PHARM INC

  公开号：WO2005100321A1

  公开（公告）日：2005-10-27

  Disclosed herein are compounds represented by Structural Formula: (I) and (I-A). Also disclosed is the use of such compounds for inhibiting the G-protein coupled receptor referred to as chemoattractant receptor-homologous molecule expressed on Th2, or simply 'CRTH2' for the treatment of inflammatory disorders. The variables in Structural Formula (I) and (I-A) are defined herein.

  本文披露了由结构式(I)和(I-A)表示的化合物。还披露了利用这些化合物抑制称为趋化剂受体同源分子表达在Th2上的G蛋白偶联受体，简称为'CRTH2'，用于治疗炎症性疾病。结构式(I)和(I-A)中的变量在此处被定义。
• PGD2 receptor antagonists for the treatment of inflammatory diseases
  申请人：Ghosh Shomir

  公开号：US20050256158A1

  公开（公告）日：2005-11-17

  Disclosed herein are compounds represented by Structural Formula (I) and (I-A): Also disclosed is the use of such compounds for inhibiting the G-protein coupled receptor referred to as chemoattractant receptor-homologous molecule expressed on Th2, or simply “CRTH2” for the treatment of inflammatory disorders. The variables in Structural Formula (I) and (I-A) are defined herein.

  本文揭示了由结构式（I）和（I-A）表示的化合物：还披露了利用这些化合物抑制称为Th2表达的G蛋白偶联受体的化学引诱受体同源分子，简称“CRTH2”，用于治疗炎症性疾病。结构式（I）和（I-A）中的变量在此处被定义。
• PGD2 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES
  申请人：MILLENNIUM PHARMACEUTICALS, INC.

  公开号：EP1556047A2

  公开（公告）日：2005-07-27
• US7211672B2
  申请人：——

  公开号：US7211672B2

  公开（公告）日：2007-05-01
• US7504508B2
  申请人：——

  公开号：US7504508B2

  公开（公告）日：2009-03-17